Glaukos (NYSE:GKOS) Given New $139.00 Price Target at BTIG Research

Glaukos (NYSE:GKOS) had its target price lifted by BTIG Research from $131.00 to $139.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

A number of other analysts have also weighed in on GKOS. Citigroup lowered shares of Glaukos from a buy rating to a neutral rating and raised their target price for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. Piper Sandler raised their target price on shares of Glaukos from $110.00 to $140.00 and gave the company an overweight rating in a research report on Thursday, August 1st. Stifel Nicolaus raised their target price on shares of Glaukos from $110.00 to $130.00 and gave the company a buy rating in a research report on Wednesday, June 5th. Morgan Stanley raised their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an equal weight rating in a research report on Monday, July 15th. Finally, Truist Financial restated a buy rating and issued a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $128.45.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $135.39 on Wednesday. The company’s 50 day moving average price is $121.40 and its two-hundred day moving average price is $107.16. Glaukos has a 12-month low of $59.22 and a 12-month high of $136.36. The firm has a market cap of $6.82 billion, a PE ratio of -47.01 and a beta of 1.05. The company has a quick ratio of 4.68, a current ratio of 5.48 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.55) EPS. Equities research analysts predict that Glaukos will post -2.25 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Joseph E. Gilliam sold 2,500 shares of Glaukos stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $113.50, for a total transaction of $283,750.00. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at $11,559,407.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the sale, the director now directly owns 30,119 shares of the company’s stock, valued at $3,614,280. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 2,500 shares of Glaukos stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $113.50, for a total transaction of $283,750.00. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $11,559,407.50. The disclosure for this sale can be found here. Insiders sold 41,000 shares of company stock valued at $4,990,740 over the last quarter. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently bought and sold shares of the stock. National Bank of Canada FI acquired a new position in shares of Glaukos during the fourth quarter valued at about $46,000. GAMMA Investing LLC acquired a new position in shares of Glaukos during the fourth quarter valued at about $55,000. Quadrant Capital Group LLC grew its holdings in shares of Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 329 shares during the last quarter. Caldwell Sutter Capital Inc. grew its holdings in shares of Glaukos by 5,860.0% during the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 1,465 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos during the second quarter valued at about $187,000. 99.04% of the stock is owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.